Can a 20-minute HIIT session shift prostate cancer hormone levels?
NCT ID NCT07518888
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study looks at how a short, home-based high-intensity workout affects steroid hormones in men with low-grade prostate cancer who are on active surveillance. About 49 men will do one supervised bodyweight HIIT session and provide saliva samples. The goal is to see if the exercise is acceptable and to measure hormone changes, not to treat the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 49 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males 18 to 80 years old * Diagnosis of localized prostate cancer * Currently under active surveillance * Ability to perform moderate-to-high intensity physical activity as demonstrated by self-assessment using the Physical Activity Readiness Questionnaire (PAR-Q+) * Able to independently perform activities of daily living, without limitations in mobility * Ability to read, write, speak, and understand English * Able and willing to sign consent and comply with study requirements Exclusion Criteria: * Males currently receiving treatment for prostate cancer * Diagnosis of metastatic prostate cancer * Individuals with medical conditions contraindicating exercise * Uncontrolled cardiovascular or circulatory diseases, hypertension, and diabetes, as determined by the study doctor or treating physician * Ongoing use of medications affecting steroid metabolism * Unable to sign consent and/or comply with study requirements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Miami Hospitals and Clinics
Miami, Florida, 33141, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Light-Based imaging aims to spot prostate cancer left behind after surgery
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer